Tel-JAK2 fusion protein expression

Clinical trials for Tel-JAK2 fusion protein expression explained in plain language.

Never miss a new study

Get alerted when new Tel-JAK2 fusion protein expression trials appear

Sign up with your email to follow new studies for Tel-JAK2 fusion protein expression, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for rare blood disorder: drug targets overactive immune cells

Disease control Ongoing

This phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…

Matched conditions: TEL-JAK2 FUSION PROTEIN EXPRESSION

Phase 2 • Sponsor: Stanford University • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Tel-JAK2 fusion protein expression

Get alerted when new Tel-JAK2 fusion protein expression trials appear

New hope for rare blood disorder: drug targets overactive immune cells